HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts.

AbstractBACKGROUND:
As a new scheme at our center, a Model for End-stage Liver Disease score of 18 points is assigned to candidates of deceased-donor liver transplantation (DDLT) who have hepatocellular carcinoma (HCC) remaining at stage 2 six months after their disease has been confirmed stage 2 HCC. Two points are added every 3 months if their disease remains at stage 2 or below. This study evaluated patient and tumor characteristics as well as surgical and short-term outcomes of DDLT in these patients.
METHODS:
Comparison of survival was made among three groups of patients who underwent liver transplantation (LT) in the same period. Group 1 consisted of 22 HCC patients who received DDLT under the new scheme. Group 2 consisted of 18 HCC patients who underwent living-donor LT. Group 3 consisted of 52 patients who underwent DDLT because of liver failure, among whom 6 had HCC but were not included in the new scheme.
RESULTS:
Group 1 had a median follow-up period of 17.9 months, and the 1-, 3-, and 5-year overall survival rates were 100%, 100%, and 80%, respectively. Group 2 had the corresponding rates at 100%, 100%, and 100% with a median follow-up of 19.6 months. Group 3 had the corresponding rates at 96.1%, 96.1%, and 96.1% with a median follow-up of 19.4 months.
CONCLUSIONS:
The policy of a 6-month wait has benefited the HCC patients who practically had no chance of undergoing living-donor LT. Their survival outcomes will be excellent as long as they can stand the test of time.
AuthorsSee Ching Chan, William W Sharr, Kenneth S H Chok, Albert C Y Chan, Chung Mau Lo
JournalTransplantation (Transplantation) Vol. 96 Issue 11 Pg. 995-9 (Dec 15 2013) ISSN: 1534-6080 [Electronic] United States
PMID23924774 (Publication Type: Comparative Study, Journal Article)
Topics
  • Adolescent
  • Adult
  • Aged
  • Carcinoma, Hepatocellular (mortality, pathology, surgery)
  • Chi-Square Distribution
  • Decision Support Techniques
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Liver Neoplasms (mortality, pathology, surgery)
  • Liver Transplantation (adverse effects, mortality)
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Patient Selection
  • Risk Factors
  • Survival Rate
  • Time Factors
  • Tissue and Organ Procurement
  • Treatment Outcome
  • Waiting Lists (mortality)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: